ResearchersLinks
Hosts and VirusesA ResearchersLinks journal
Submit manuscriptReview for this journal

Commentary · Volume 2, Issue 2, 11 March 2015 · Open Access

Have we found an Optimal Insertion Site in a Newcastle Disease Virus Vector to Express a Foreign Gene for Vaccine and Gene Therapy Purposes?

Affiliations & Notes ⌄
  1. 1US National Poultry Research Center, Agricultural Research Services, United States Department of Agriculture, 934 College Station Road, Athens, GA 30605, USA. E-mail | qingzhong.yu@ars.usda.gov
Article Info ⌄
Journal:
Hosts and Viruses
Published:
11 March 2015
Download PDF ePub eFLIP Set Alert Get Rights Reprints

From the article

  • Therefore, a balance in virus replication and the abundance of foreign gene expression must be considered for selection of a foreign gene insertion site.
  • Role of untranslated regions in regulation of gene expression, replication, and pathogenicity of Newcastle disease virus expressing green fluorescent protein.
  • Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.
  • P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression.

Selected from the article's own text.

Abstract

Different approaches have been used to investigate the most suitable insertion site for optimal expression of a foreign gene without compromising the replication of the Newcastle disease virus. Recently, inserting a green fluorescent protein (GFP) gene upstream from the GE sequences of the viral genes and subsequent quantitative measurements of the GFP fluorescence intensity, we have concluded that the P and M junction region is the optimal insertion site for a high level of foreign gene expression by a NDV vector.

Acknowledgements

The author wishes to thank Patti Miller for critical reading of the manuscript. The research carried out in the author’s laboratory was supported by USDA, ARS CRIS project 6040-32000-067-00D.

References

  1. Bukreyev, A. & Collins, P. L. (2008). Newcastle disease virus as a vaccine vector for humans. Current opinion in molecular therapeutics 10, 46-55.
  2. Bukreyev, A., Huang, Z., Yang, L., Elankumaran, S., St Claire, M., Murphy, B. R., Samal, S. K. & Collins, P. L. (2005). Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 79, 13275-13284.
  3. Cardenas-Garcia, S., Diel, D. G., Susta, L., Lucio-Decanini, E., Yu, Q., Brown, C. C., Miller, P. J. & Afonso, C. L. (2014). Development of an improved vaccine evaluation protocol to compare the efficacy of Newcastle disease vaccines. Biologicals. doi: 10.1016/j.biologicals.2014.11.003.[CrossRef]
  4. Carnero, E., Li, W., Borderia, A. V., Moltedo, B., Moran, T. & Garcia-Sastre, A. (2009). Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol 83, 584-597.
  5. DiNapoli, J. M., Kotelkin, A., Yang, L., Elankumaran, S., Murphy, B. R., Samal, S. K., Collins, P. L. & Bukreyev, A. (2007). Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci USA 104, 9788-9793.
  6. Estevez, C., King, D. J., Luo, M. & Yu, Q. (2011). A single amino acid substitution in the haemagglutinin-neuraminidase protein of Newcastle disease virus results in increased fusion promotion and decreased neuraminidase activities without changes in virus pathotype. J Gen Virol 92, 544-551.
  7. Estevez, C. N., King, D. J., Seal, B. & Yu, Q. (2007). Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone. Virus Res 129, 182-190.
  8. Gao, Q., Park, M. S. & Palese, P. (2008). Expression of transgenes from newcastle disease virus with a segmented genome. J Virol 82, 2692-2698.
  9. Goff, P. H., Gao, Q. & Palese, P. (2012). A majority of infectious Newcastle disease virus particles contain a single genome, while a minority contain multiple genomes. J Virol 86, 10852-10856.
  10. Hu, H., Roth, J. P., Estevez, C. N., Zsak, L., Liu, B. & Yu, Q. (2011). Generation and evaluation of a recombinant Newcastle disease virus expressing the glycoprotein (G) of avian metapneumovirus subgroup C as a bivalent vaccine in turkeys. Vaccine 29, 8624-8633.
  11. Huang, Z., Elankumaran, S., Panda, A. & Samal, S. K. (2003). Recombinant Newcastle disease virus as a vaccine vector. Poultry Science 82, 899-906.
  12. Huang, Z., Elankumaran, S., Yunus, A. S. & Samal, S. K. (2004). A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. Journal of virology 78, 10054-10063.
  13. Kim, S. H., Paldurai, A., Xiao, S., Collins, P. L. & Samal, S. K. (2014). Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens. Vaccine 32, 4428-4435.
  14. Kim, S. H. & Samal, S. K. (2010). Role of untranslated regions in regulation of gene expression, replication, and pathogenicity of Newcastle disease virus expressing green fluorescent protein. J Virol 84, 2629-2634.
  15. Lamb, R. A. & Parks, G. D. (2013). Paramyxoviridae. In Fields Virology, Sixth edn, pp. 957-995. Edited by D. M. Knipe, P. M. Howley, J. I. Cohen, D. E. Griffin, R. A. Lamb, M. A. Marti, V. R. Racaniello & B. Roizman. Philadelphia, PA, USA: Lippincott Williams & Wilkins.
  16. Marcos, F., Ferreira, L., Cros, J., Park, M. S., Nakaya, T., Garcia-Sastre, A. & Villar, E. (2005). Mapping of the RNA promoter of Newcastle disease virus. Virology 331, 396-406.
  17. Miller, P. J., Estevez, C., Yu, Q., Suarez, D. L. & King, D. J. (2009). Comparison of viral shedding following vaccination with inactivated and live Newcastle disease vaccines formulated with wild-type and recombinant viruses. Avian Dis 53, 39-49.
  18. Nakaya, T., Cros, J., Park, M. S., Nakaya, Y., Zheng, H., Sagrera, A., Villar, E., Garcia-Sastre, A. & Palese, P. (2001). Recombinant Newcastle disease virus as a vaccine vector. J Virol 75, 11868-11873.
  19. Paldurai, A., Kim, S. H., Nayak, B., Xiao, S., Shive, H., Collins, P. L. & Samal, S. K. (2014). Evaluation of the contributions of individual viral genes to newcastle disease virus virulence and pathogenesis. J Virol 88, 8579-8596.
  20. Park, M. S., Steel, J., Garcia-Sastre, A., Swayne, D. & Palese, P. (2006). Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci USA 103, 8203-8208.
  21. Peeters, B. P., de Leeuw, O. S., Koch, G. & Gielkens, A. L. (1999). Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73, 5001-5009.
  22. Ramp, K., Skiba, M., Karger, A., Mettenleiter, T. C. & Romer-Oberdorfer, A. (2011). Influence of insertion site of the avian influenza virus haemagglutinin (HA) gene within the Newcastle disease virus genome on HA expression. J Gen Virol 92, 355-360.
  23. Romer-Oberdorfer, A., Mundt, E., Mebatsion, T., Buchholz, U. J. & Mettenleiter, T. C. (1999). Generation of recombinant lentogenic Newcastle disease virus from cDNA. J Gen Virol 80 ( Pt 11), 2987-2995.
  24. Schirrmacher, V. & Fournier, P. (2009). Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol 542, 565-605.
  25. Skiadopoulos, M. H., Surman, S. R., Durbin, A. P., Collins, P. L. & Murphy, B. R. (2000). Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes. Virology 272, 225-234.
  26. Vigil, A., Martinez, O., Chua, M. A. & Garcia-Sastre, A. (2008). Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Molecular therapy : the journal of the American Society of Gene Therapy 16, 1883-1890.
  27. Wen, G., Chen, C., Guo, J., Zhang, Z., Shang, Y., Shao, H., Luo, Q., Yang, J., Wang, H., Wang, H., Zhang, T., Zhang, R., Cheng, G. & Yu, Q. (2015). Development of a Novel Thermostable Newcastle Disease Virus Vaccine Vector for Expression of a Heterologous Gene. J Gen Virol. doi: 10.1099/vir.0.000067[CrossRef]
  28. Yan, Y. & Samal, S. K. (2008). Role of intergenic sequences in newcastle disease virus RNA transcription and pathogenesis. J Virol 82, 1323-1331.
  29. Yu, Q., Roth, J. P., Hu, H., Estevez, C. N., Zhao, W. & Zsak, L. (2013). Protection by recombinant Newcastle disease viruses (NDV) expressing the glycoprotein (G) of avian metapneumovirus (aMPV) subtype A or B against challenge with virulent NDV and aMPV. World Journal of Vaccines, 130-139.
  30. Zhao, H. & Peeters, B. P. (2003). Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J Gen Virol 84, 781-788.
  31. Zhao, W., Spatz, S., Zhang, Z., Wen, G., Garcia, M., Zsak, L. & Yu, Q. (2014). Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges. J Virol 88, 8397-8406.
  32. Zhao, W., Zhang, Z., Zsak, L. & Yu, Q. (2015). P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression. J Gen Virol 96, 40-45.

Related articles

Services

Article usage statistics

Loading…

Have we found an Optimal Insertion Site in a Newcastle Disease Virus Vector to Express a Foreign Gene for Vaccine and Gene Therapy Purposes? · ResearchersLinks